# General Proximity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/general-proximity

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.generalproximity.bio
- Total disclosed funding: $16M
- Latest round: Seed (Dec 18, 2024)
- Investors on record: 5

## About

Based in California, US, and founded in 2019 by Armand B. Cognetta (CEO), General Proximity operates as a biotechnology company that researches and develops induced-proximity medicines for dementia. In December 2024, General Proximity raised USD 8 million in seed funding led by Felicis Ventures, with participation from Y Combinator, Age1, Modi Ventures, and Wilson Sonsini Goodrich and Rosati.

General Proximity focuses on creating advanced proximity medicines using a discovery platform. The firm platform identifies proteins that play a key role in controlling biological processes by interacting with other proteins. General Proximity develops treatments that can activate, modify, or break down specific proteins to address difficult-to-treat medical targets. The frim work covers various health issues, including cancer, and collaborate with organizations like Johnson and Johnson and UCSF, serving clients mainly in North America and Europe.

The company plnas to use the December 2024 funding to accelerate its drug-discovery platform and support its initiatives of developing for dementia-related medicines.

## Funding rounds

- Seed, Dec 18, 2024, $16M — Felicis Ventures, Y Combinator, Wilson Sonsini Goodrich & Rosati, Modi Ventures, Age1

## Investors

- Felicis Ventures (https://capitalatlas.ai/funds/felicis-ventures) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- Wilson Sonsini Goodrich & Rosati — Seed
- Modi Ventures (https://capitalatlas.ai/funds/modi-ventures) — Seed
- Age1 (https://capitalatlas.ai/funds/age1) — Seed